Emphasis is placed on the development and manufacture of Plasmodium falciparum malaria antigens for testing in human clinical trials at WRAIR and around the world. Studies include identification of optimal presentation of the target antigen to the immune system in order to induce long lasting, protective immunity and to elucidate in vitro correlates of immunity mediated through both humoral and cellular mechanisms. Novel platforms for antigen expression, delivery, and presentation to antigen presenting cells are being explored. Human pathogens are used preferentially to other model parasites whenever feasible. Both erythrocytic and pre-erythrocytic stage antigens are studied. The primary objective is to elucidate protective mechanisms involving antibodies and/or T-cell subsets that mediate cellular effector functions.

 

References

Darko CA, et al: Infection and Immunit6y 73(1): 287, 2005

Bergmann-Leitner ES, et al: American Journal of Tropical Medicine and Hygiene 75(3): 437, 2006

 

key words

Immunity; Antibody specificity; Malaria; P. falciparum; Vaccines; Irbc development; Protein expression; Growth inhibition; Protein folding/structure;

Citizenship:  Open to U.S. citizens, permanent residents and non-U.S. citizens

Level:  Open to Postdoctoral and Senior applicants